Double blind clinical trial in a series of 115 patients with seborrheic dermatitis: Prevention of relapses using a topical modulator of Toll like receptor 2

M. A. Ionescu, A. Baroni, L. Brambilla, S. P. Cannavò, A. Cristaudo, C. Dalle Vedove, M. Frasca, G. Girolomoni, L. Gnecchi, K. Peris, C. Trifirò, A. M. Matta, G. Robert

Research output: Contribution to journalArticle

Abstract

Aim. Seborrheic dermatitis is a chronic inflammatory disease aggravated by Malassezia species. Toll-like receptors (TLR) are part of innate immune system that can be activated by yeasts. Previous studies showed that an association of Ombelliferae extract with a lipid (TLR2-Regul™) decreases the IL-8 expression in human skin in contact with M. furfur. The aim of this study was to assess the activity of a topical formulated with TLR2-Regul™ in the prevention of seborrheic dermatitis (SD) relapses. Methods. Immune-competent SD adult patients were treated for SD (topical imidazoles or steroids). Cleared patients were randomized and received a topical containing TLR2-Regul™ (A) or its vehicle (B). Erythema, scales and pruritus were assessed during two months. Results. The study included 115 patients, mean age 43.4, sex ratio m/f 1.5. At week 4 the relapse rate was 26% (N.=15) in group A and 43% (N.=25) in group B. At W8 the relapse rate was 21% (N.=12) in group A and 40% (N.=23) (P=0.0309). Conclusion. In this series of 115 adults with seborrheic dermatitis, patients treated with a topical containing TLR-Regul™ showed a significantly less relapse rate compared with the excipient group (P

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalGiornale Italiano di Dermatologia e Venereologia
Volume146
Issue number3
Publication statusPublished - 2011

Keywords

  • Dermatitis
  • Prevention and control
  • Recurrence
  • Seborrheic
  • Toll-like receptors

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Double blind clinical trial in a series of 115 patients with seborrheic dermatitis: Prevention of relapses using a topical modulator of Toll like receptor 2'. Together they form a unique fingerprint.

  • Cite this

    Ionescu, M. A., Baroni, A., Brambilla, L., Cannavò, S. P., Cristaudo, A., Dalle Vedove, C., Frasca, M., Girolomoni, G., Gnecchi, L., Peris, K., Trifirò, C., Matta, A. M., & Robert, G. (2011). Double blind clinical trial in a series of 115 patients with seborrheic dermatitis: Prevention of relapses using a topical modulator of Toll like receptor 2. Giornale Italiano di Dermatologia e Venereologia, 146(3), 185-189.